{"name": "vilanterol", "category": "drug", "content": "Vilanterol (INN, USAN) is an ultra-long-acting \u03b22 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).. The combination is also approved for the treatment of asthma in Canada, Europe, Japan and New Zealand. Vilanterol is available in following combinations:  with inhaled corticosteroid fluticasone furoate\u2014fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S., NZ), Relvar Ellipta (EU, RU, JPN)) with muscarinic antagonist umeclidinium bromide\u2014umeclidinium bromide/vilanterol (trade name Anoro Ellipta) with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide\u2014fluticasone furoate/umeclidinium bromide/vilanterol (trade name Trelegy Ellipta)   == See also == Salmeterol\u2014the long-acting \u03b22 adrenoreceptor agonist (LABA) from which vilanterol was derived.   == References =="}